LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

Verve Therapeutics Inc

Chiusa

4.55 -1.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.59

Massimo

4.7

Metriche Chiave

By Trading Economics

Entrata

98K

-50M

Vendite

6.2M

13M

EPS

-0.58

Margine di Profitto

-382.531

Dipendenti

274

EBITDA

789K

-54M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+445.36% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-207M

388M

Apertura precedente

6.49

Chiusura precedente

4.55

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Verve Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2025, 23:47 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mag 2025, 23:40 UTC

Discorsi di Mercato

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mag 2025, 18:00 UTC

Utili

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mag 2025, 17:01 UTC

Notizie principali

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mag 2025, 16:20 UTC

Utili

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mag 2025, 12:09 UTC

Notizie principali

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mag 2025, 17:15 UTC

Notizie principali

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mag 2025, 09:30 UTC

Notizie principali
Utili

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mag 2025, 08:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 mag 2025, 08:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 23:18 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mag 2025, 22:30 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- Update

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 mag 2025, 21:54 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mag 2025, 21:22 UTC

Discorsi di Mercato

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mag 2025, 21:17 UTC

Discorsi di Mercato

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mag 2025, 21:17 UTC

Notizie principali

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mag 2025, 21:05 UTC

Discorsi di Mercato

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mag 2025, 20:55 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 mag 2025, 20:37 UTC

Notizie principali

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mag 2025, 20:33 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mag 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mag 2025, 20:18 UTC

Notizie principali

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mag 2025, 20:16 UTC

Notizie principali

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mag 2025, 20:15 UTC

Utili

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mag 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: William K. Daniel Joins Board

16 mag 2025, 20:10 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: Strategic Investment by KKR Completed

Confronto tra pari

Modifica del prezzo

Verve Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

445.36% in crescita

Previsioni per 12 mesi

Media 25.25 USD  445.36%

Alto 39 USD

Basso 15 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Verve Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

9

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.1501 / 5.16Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.